Meeting
2016 ASCO Annual Meeting
Treat ER+ight: Treatment of Canadian postmenopausal women with ER+ HER2- advanced breast cancer in the real-world setting with hormone therapy ± targeted therapy.
Authors
Nadia Califaretti
Grand River Regional Cancer Centre, Waterloo, ON, Canada
Nadia Califaretti , Nathaniel Bouganim , Susan Faye Dent , Catherine Doyle , Jan-Willem Henning , John S Sampalis , Sabrina R. Perri , Stephen K. L. Chia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS614)
DOI
10.1200/JCO.2016.34.15_suppl.TPS614
Abstract #
TPS614
Poster Bd #
101b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.
First Author: Sunil Verma
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei